← All trials
NCT05380882
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 31, 2022
- Primary completion
- Apr 30, 2023
- Completion date
- Dec 31, 2023
- First posted
- May 19, 2022
- Last posted
- May 19, 2022
- Enrollment
- 60
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Jiangsu Chia-tai Tianqing Pharmaceutical Co.,LtdLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.